Episode: 38 - Third Rock’s John Keilty on What Lies Ahead for Bioinvestment

As the new year settles in, the industry is anticipating new innovative biotech and learning from past failures. John Keilty, venture partner at Third Rock Ventures, discusses the current trends he sees in biopharma investment, separating the hype from reality of AI (and if the AI bubble will eventually pop), other ventures that should be considered, and how new companies are being built today compared to past years in this episode of Trends from the Trenches. With host Eleanor Howe, founder and CEO of Diamond Age Data Science, Keilty also reflects on the biotech failures of past years and shares his thoughts on the role of computational biologists these days, as well as where bioinvesting is working and not working now. Links from this episode:   Bio-IT World BioTeam Bio-IT World Europe Diamond Age Data Science Third Rock Ventures  Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.